Companies · Hardware / Semiconductors
South San Francisco · CA, USA · Hardware / Semiconductors · founded 2017 · http://www.predxionbio.com
Diligence memoA one-page analyst read on PreDxion Bio — recommendation, valuation, rhythm, risks.→PreDxion Bio: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
PreDxion Bio is one of 130 Hardware / Semiconductors companies tracked from South San Francisco, CA, USA, on record since 2017. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Rapid, scalable diagnostic for SARS-CoV-2 and beyond
PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale. PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 130 companies in Hardware / Semiconductors. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 48% of sector peers (real $). Modeled value above 48% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
PreDxion Bio is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| AccessOwl | Hardware / Semiconductors | — | — | — | same sector |
| ACCO Semiconductor, Inc. | Hardware / Semiconductors | Series A | $55.1M | $123.3M | same sector |
| Activeloop | Hardware / Semiconductors | — | — | — | same sector |
| Advanced Silicon Group, Inc. | Hardware / Semiconductors | Seed | $1.0M | $14.6M | same sector |
| AeroFS | Hardware / Semiconductors | — | — | — | same sector |
| Afrostream | Hardware / Semiconductors | — | — | — | same sector |
| Aisle50 | Hardware / Semiconductors | — | — | — | same sector |
| AKHAN Semiconductor, Inc. | Hardware / Semiconductors | Series B | $26.0M | $207.5M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Correlia Biosystems, Inc. Next-gen blood testing to provide 1000x more data to pharma companies | Biotechnology | Series A | $11.6M | 74% |
| Shield Bio Bringing 3rd generation, nanopore sequencing to healthcare to solve… | Biotech / Pharma | — | — | 74% |
| Pardes Biosciences, Inc We break viruses | Biotechnology | Series C | $1.7B | 74% |
| Biobot Analytics, Inc. Population health analytics powered by wastewater. | Software / Tech | Series B | $73.4M | 74% |
| Cofactor Genomics, Inc. Cofactor closes the precision medicine gap with predictive diagnostics | Biotechnology | Series A | $9.7M | 73% |
| Signatur Biosciences Simple tests for complex diseases. | Biotech | — | — | 72% |
| Digistain Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow | Medical Devices | — | — | 72% |
| InnaMed At-home blood testing: measure + analyze + enhance. | Biotech | — | — | 72% |
See where PreDxion Bio sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at PreDxion Bio, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.